Suppression of Fas-mediated apoptosis of keratinocyte cells by chikusetsusaponins isolated from the roots of Panax japonicus.
Fas-mediated apoptotic cell death of a human keratinocyte cell line, HaCaT cells, and of a murine keratinocyte cell line, Pam212 cells, was suppressed by pre-treatment with a methanol extract from the roots of Panax japonicus C.A. Meyer. Activity-guided fractionation led to the isolation of chikusetsusaponins IV, IVa, V and polysciasaponin P5 as the active ingredients. Of these compounds, chikusetsusaponin IV, was most active when applied at a concentration of 12.5 microg/mL. The intracellular hallmark events of apoptosis such as DNA fragmentation and chromatin condensation were significantly reduced by the treatment with chikusetsusaponin IV. The apoptotic cell death of Jurkat cells was also suppressed by treatment with the active saponins. These results suggest that the use of chikusetsusaponins IV, IVa, V, polysciasaponin P5, or a crude extract of P. japonicus containing these saponins is expected to relieve cutaneous symptoms caused by excessive apoptotic cell death in the skin through the Fas/FasL pathway.
Hosono-Nishiyama
Kanako
K
Kitasato Institute for Life Sciences & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan.
Matsumoto
Tsukasa
T
Kiyohara
Hiroaki
H
Nishizawa
Ai
A
Atsumi
Takamasa
T
Yamada
Haruki
H
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D045744:Cell Line, Tumor / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D053222:Fas Ligand Protein; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects; D008562:Membrane Glycoproteins; D051379:Mice; D005894:Panax; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018517:Plant Roots; D012503:Saponins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D048069:Tumor Necrosis Factors
D000972:Antineoplastic Agents, Phytogenic; C505661:FASLG protein, human; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008562:Membrane Glycoproteins; D010936:Plant Extracts; D012503:Saponins; D048069:Tumor Necrosis Factors